A Study to Evaluate the Therapeutic Benefit of Tisagenlecleucel Compared to Existing Standard of Care in German Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

NCT07103486 · clinicaltrials.gov ↗

COMPLETED

Status

264

Enrollment

INDUSTRY

Sponsor class

Conditions

Diffuse Large B-Cell Lymphoma

Sponsor

Novartis Pharmaceuticals